Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: Evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial

被引：11

作者：

Joly, V

Moroni, M

Concia, E

Lazzarin, A

Hirschel, B

Jost, J

Chiodo, F

Bentwich, Z

Love, WC

Hawkins, DA

Wilkins, EGL

Gatell, AJ

Vetter, N

Greenwald, C

Freimuth, WW

De Cian, W

机构：

[1] Hop Bichat, Dept Internal Med, F-75877 Paris 18, France

[2] Osped L Sacco, Div Infect Dis, Milan, Italy

[3] Osped San Raffaele, Div Infect Dis, Milan, Italy

[4] Pharmacia & Upjohn Co, Milan, Italy

[5] Osped S Orsola Malpighi, Div Infect Dis, Bologna, Italy

[6] Osped Borgo Roma, Div Infect Dis, Verona, Italy

[7] Hop Cantonal Univ Geneva, Div Infect Dis, CH-1211 Geneva, Switzerland

[8] Universitatsspital Abt, Div Infect Dis, Zurich, Switzerland

[9] Kaplan Hosp, Clin Immunol, Rehovot, Israel

[10] Ruchill Hosp, Dept Infect & Trop Med, Glasgow G20 9NB, Lanark, Scotland

[11] Kolber Ctr, London, England

[12] N Manchester Grp Hosp, Dept Infect Dis, Manchester, Lancs, England

[13] Hosp Clin & Provencialo, Div Infect Dis, Barcelona, Spain

[14] Wiener Wald Pulm Zentrum Sanatorium, Dept Med, Vienna, Austria

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2000年 / 44卷 / 11期

关键词：

D O I：

10.1128/AAC.44.11.3155-3157.2000

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.

引用

页码：3155 / 3157

页数：3

共 50 条

[31] Screening for antiretroviral drug resistance among treatment-naive human immunodeficiency virus type 1-infected individuals in Lebanon
Mokhbat, Jacques M.
Melhem, Nada M.
El-Khatib, Ziad
Zalloua, Pierre
JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2014, 8 (03): : 339 - 348
[32] A COMPARATIVE TRIAL OF DIDANOSINE OR ZALCITABINE AFTER TREATMENT WITH ZIDOVUDINE IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION
ABRAMS, DI
GOLDMAN, AI
LAUNER, C
KORVICK, JA
NEATON, JD
CRANE, LR
GRODESKY, M
WAKEFIELD, S
MUTH, K
KORNEGAY, S
COHN, DL
HARRIS, A
LUSKINHAWK, R
MARKOWITZ, N
SAMPSON, JH
THOMPSON, M
DEYTON, L
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (10): : 657 - 662
[33] Frequency of mutations conferring resistance to nucleoside reverse transcriptase inhibitors in human immunodeficiency virus type 1-infected patients in Korea
Cho, YK
Sung, H
Ahn, SH
Bae, IG
Woo, JH
Won, YH
Kim, G
Kang, MW
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (04) : 1319 - 1325
[34] Enhanced saquinavir exposure in human immunodeficiency virus type 1-infected patients with diarrhea and/or wasting syndrome
Trout, H
Mentré, F
Panhard, X
Kodjo, A
Escaut, L
Pernet, P
Gobert, JG
Vittecoq, D
Knellwolf, AL
Caulin, C
Bergmann, JF
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (02) : 538 - 545
[35] Evaluation of human immunodeficiency virus (HIV) type 1 RNA levels in cerebrospinal fluid and viral resistance to zidovudine in children with HIV encephalopathy
Sei, S
Stewart, SK
Farley, M
Mueller, BU
Lane, JR
Robb, ML
Brouwers, P
Pizzo, PA
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (06): : 1200 - 1206
[36] Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection
Frost, SDW
Nijhuis, M
Schuurman, R
Boucher, CAB
Brown, AJL
JOURNAL OF VIROLOGY, 2000, 74 (14) : 6262 - 6268
[37] Pharmacokinetic Assessment of Nevirapine and Metabolites in Human Immunodeficiency Virus Type 1-Infected Patients with Hepatic Fibrosis
Cammett, Anna Maria
MacGregor, Thomas R.
Wruck, Jan M.
Felizarta, Franco
Miailhes, Patrick
Mallolas, Josep
Piliero, Peter J.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (10) : 4147 - 4152
[38] Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine
Jankelevich, S
Mueller, BU
Mackall, CL
Smith, S
Zwerski, S
Wood, LV
Zeichner, SL
Serchuck, L
Steinberg, SM
Nelson, RP
Sleasman, JW
Nguyen, BY
Pizzo, PA
Yarchoan, R
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (07): : 1116 - 1120
[39] Long-Term Control of Viral Replication in a Group O, Human Immunodeficiency Virus Type 1-Infected Individual
Buckheit, Robert W., III
Sexauer, Stephen B.
Sedaghat, Ahmad R.
Wilke, Claus O.
Laeyendecker, Oliver
Basseth, Christie R.
Blankson, Joel N.
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 (06) : 511 - 513
[40] Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring
Moodley, J
Moodley, D
Pillay, K
Coovadia, H
Saba, J
van Leeuwen, R
Goodwin, C
Harrigan, PR
Moore, KHP
Stone, C
Plumb, R
Johnson, MA
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (05): : 1327 - 1333

← 1 2 3 4 5 →